ReviewBlood2009
Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells.
Review in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 148 citations in OpenAlex.
- Efficient and robust generation of functional hematopoietic cells from human pluripotent stem cells in albumin-free conditions.Stem cells translational medicine · 2026Article
- Modeling myeloid cell development in health and disease using induced pluripotent stem cells.Frontiers in immunology · 2026Review
- Cytokine secretion in stem cells of cattle infected with bovine leukaemia virus.Journal of veterinary research · 2024Article
- Identification and characterization of human hematopoietic mesoderm.Science China. Life sciences · 2024Article
- Engineered hematopoietic and immune cells derived from human pluripotent stem cells.Experimental hematology · 2023Review
- In vitro vascular differentiation system efficiently produces natural killer cells for cancer immunotherapies.Oncoimmunology · 2023Article
- Chemically-defined generation of human hemogenic endothelium and definitive hematopoietic progenitor cells.Biomaterials · 2022Article
- Advances in stromal cell therapy for management of Alzheimer's disease.Frontiers in pharmacology · 2022Review
- Progress in the production of haematopoietic stem and progenitor cells from human pluripotent stem cells.Journal of immunology and regenerative medicine · 2021Article
- First blood: the endothelial origins of hematopoietic progenitors.Angiogenesis · 2021Review
- Direct Generation of Immortalized Erythroid Progenitor Cell Lines from Peripheral Blood Mononuclear Cells.Cells · 2021Article
- Biphasic Regulation of Mesenchymal Genes Controls Fate Switches During Hematopoietic Differentiation of Human Pluripotent Stem Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Analysis of endothelial-to-haematopoietic transition at the single cell level identifies cell cycle regulation as a driver of differentiation.Genome biology · 2020Article
- Stage-specific regulation of Gremlin1 on the differentiation and expansion of human urinary induced pluripotent stem cells into endothelial progenitors.Journal of cellular and molecular medicine · 2020Article
- MSX2 suppression through inhibition of TGFβ signaling enhances hematopoietic differentiation of human embryonic stem cells.Stem cell research & therapy · 2020Article
- Toward a better definition of hematopoietic progenitors suitable for B cell differentiation.PloS one · 2020Article
- iNK-CD64/16A cells: a promising approach for ADCC?Expert opinion on biological therapy · 2019Article
- Characterization and Isolation of Very Small Embryonic-like (VSEL) Stem Cells Obtained from Various Human Hematopoietic Cell Sources.Stem cell reviews and reports · 2019Article
- Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.Blood science (Baltimore, Md.) · 2019Review
- Modeling blood diseases with human induced pluripotent stem cells.Disease models & mechanisms · 2019Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) provide remarkable cellular platforms to better understand human hematopoiesis and to develop clinically applicable hematopoietic cell-based therapies. Over the past decade, hESCs have been used to characterize molecular and cellular mechanisms underpinning the differentiation of hematopoietic progenitors and mature, functional hematopoietic cells. These advances are now poised to lead to clinical translation of hESC- and iPSC-derived hematopoietic cells for novel therapies in the next few years. On the basis of areas of recent success, initial clinical use of hematopoietic cells derived from human pluripotent stem cells will probably be in the areas of transfusion therapies (erythrocytes and platelets) and immune therapies (natural killer cells). In contrast, efficient development and isolation of hematopoietic stem cells capable of long-term, multilineage engraftment still remains a significant challenge. Technical, safety, and regulatory concerns related to clinical applications of human PSCs must be appropriately addressed. However, proper consideration of these issues should facilitate and not inhibit clinical translation of new therapies. This review outlines the current status of hematopoietic cell development and what obstacles must be surmounted to bring hematopoietic cell therapies from human PSCs from "bench to bedside."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.